Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Details)

v3.7.0.1
Intangible Assets (Details) - USD ($)
Dec. 31, 2016
May 31, 2016
Business Combination Segment Allocation [Line Items]    
Liability assumed (HPI)   $ (1,000,000)
Houston Pharmaceuticals, Inc [Member]    
Business Combination Segment Allocation [Line Items]    
Liability assumed (HPI) $ (3,874,000)  
Moleculin LLC [Member]    
Business Combination Segment Allocation [Line Items]    
Cash 362  
Property and equipment 7,820  
Intangibles 11,147,540  
Total assets acquired 11,155,722  
Other liabilities assumed, including $469,939 of notes payable (1,224,314)  
Net assets acquired/total consideration transferred $ 6,057,408